Free Trial

Emergent Biosolutions (EBS) Competitors

Emergent Biosolutions logo
$6.24 -0.01 (-0.08%)
Closing price 06/17/2025 03:59 PM Eastern
Extended Trading
$6.33 +0.10 (+1.59%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EBS vs. CLDX, INVA, MNKD, DVAX, NVAX, OPK, GERN, RGLS, ZBIO, and MYGN

Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Celldex Therapeutics (CLDX), Innoviva (INVA), MannKind (MNKD), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.

Emergent Biosolutions vs. Its Competitors

Emergent Biosolutions (NYSE:EBS) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

78.4% of Emergent Biosolutions shares are held by institutional investors. 3.2% of Emergent Biosolutions shares are held by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Celldex Therapeutics has lower revenue, but higher earnings than Emergent Biosolutions. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent Biosolutions$1.04B0.32-$190.60M-$2.71-2.30
Celldex Therapeutics$7.02M189.68-$157.86M-$2.70-7.43

Emergent Biosolutions currently has a consensus target price of $14.33, indicating a potential upside of 129.89%. Celldex Therapeutics has a consensus target price of $50.11, indicating a potential upside of 149.81%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Emergent Biosolutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emergent Biosolutions
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Celldex Therapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89

Emergent Biosolutions has a net margin of -13.63% compared to Celldex Therapeutics' net margin of -2,366.07%. Emergent Biosolutions' return on equity of -0.52% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Emergent Biosolutions-13.63% -0.52% -0.17%
Celldex Therapeutics -2,366.07%-23.46%-22.35%

Emergent Biosolutions has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Celldex Therapeutics received 199 more outperform votes than Emergent Biosolutions when rated by MarketBeat users. Likewise, 75.30% of users gave Celldex Therapeutics an outperform vote while only 66.82% of users gave Emergent Biosolutions an outperform vote.

CompanyUnderperformOutperform
Emergent BiosolutionsOutperform Votes
429
66.82%
Underperform Votes
213
33.18%
Celldex TherapeuticsOutperform Votes
628
75.30%
Underperform Votes
206
24.70%

In the previous week, Celldex Therapeutics had 17 more articles in the media than Emergent Biosolutions. MarketBeat recorded 18 mentions for Celldex Therapeutics and 1 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 1.72 beat Celldex Therapeutics' score of 0.71 indicating that Emergent Biosolutions is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Emergent Biosolutions
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Celldex Therapeutics
2 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Celldex Therapeutics beats Emergent Biosolutions on 10 of the 19 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EBS vs. The Competition

MetricEmergent BiosolutionsMED IndustryMedical SectorNYSE Exchange
Market Cap$339.24M$1.21B$5.33B$19.76B
Dividend YieldN/AN/A5.32%3.78%
P/E Ratio-2.308.4925.9327.09
Price / Sales0.32386.26419.0535.17
Price / Cash3.2589.8735.6321.14
Price / Book0.705.537.814.44
Net Income-$190.60M-$69.30M$3.15B$986.38M
7 Day Performance-6.66%-5.57%-2.65%-1.05%
1 Month Performance-6.31%10.24%4.37%0.82%
1 Year Performance2.89%-6.29%35.72%11.28%

Emergent Biosolutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EBS
Emergent Biosolutions
4.4231 of 5 stars
$6.24
-0.1%
$14.33
+129.9%
+3.9%$339.24M$1.04B-2.302,420Positive News
CLDX
Celldex Therapeutics
2.7069 of 5 stars
$20.71
-3.0%
$53.90
+160.3%
-42.5%$1.37B$7.56M-8.06150Analyst Revision
INVA
Innoviva
4.0324 of 5 stars
$21.58
flat
$55.00
+154.9%
+32.7%$1.35B$369.84M31.28100Positive News
High Trading Volume
MNKD
MannKind
3.0274 of 5 stars
$4.37
-0.2%
$10.00
+128.8%
-21.1%$1.33B$297.60M62.43400
DVAX
Dynavax Technologies
4.0722 of 5 stars
$10.28
+0.4%
$24.00
+133.5%
-11.9%$1.23B$294.62M57.11350
NVAX
Novavax
4.5647 of 5 stars
$7.41
-0.5%
$19.00
+156.4%
-53.8%$1.20B$1.21B-3.281,990Analyst Forecast
Gap Down
OPK
OPKO Health
4.4751 of 5 stars
$1.38
+1.5%
$2.75
+99.3%
+3.2%$1.09B$689.41M-7.264,200Positive News
GERN
Geron
3.2274 of 5 stars
$1.62
+1.3%
$5.06
+212.5%
-69.0%$1.03B$116.29M-5.0670Positive News
RGLS
Regulus Therapeutics
1.5476 of 5 stars
$8.30
+1.0%
$8.50
+2.4%
+246.0%$574.64MN/A-7.7630Positive News
ZBIO
Zenas Biopharma
1.4339 of 5 stars
$11.92
+7.2%
$36.67
+207.6%
N/A$498.66M$15M-3.36N/ATrending News
Gap Up
MYGN
Myriad Genetics
4.0299 of 5 stars
$5.19
+2.0%
$14.38
+177.2%
-79.3%$478.40M$831.30M-3.992,600

Related Companies and Tools


This page (NYSE:EBS) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners